Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dolutegravir: an exciting new kid on the block.

Expert opinion on pharmacotherapy - 1 Mar 2014

Blanco Arévalo Jose Luis, Whitlock Gary George

Abstract excerpt

INTRODUCTION: Dolutegravir is the first second-generation integrase inhibitor approved for the treatment of naïve as well as experienced HIV-infected individuals. AREAS COVERED: Data from pharmacokinetics, efficacy, safety, tolerability and resistance are reviewed from in vitro studies, Phase II and III clinical trials published in PubMed (Dolutegravir; S/GSK1349572) or presented in international meetings. EXPERT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic
Share to Clinical Trials, Phase III as Topic
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Piperazines

Share to Pyridones

Source

Identifiers

PMID: 24446762
DOI: 10.1517/14656566.2014.868883

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dolutegravir: an exciting new kid on the block.PMID 24446762Read ↗

Dolutegravir for the treatment of HIVSemantic proximity Read ↗

Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Semantic proximity Read ↗

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read ↗

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVSemantic proximity Read ↗

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?Semantic proximity Read ↗

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.Semantic proximity Read ↗

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIVSemantic proximity Read ↗

Will drug resistance against dolutegravir in initial therapy ever occur?Semantic proximity Read ↗

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read ↗

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug ResistanceSemantic proximity Read ↗

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.Semantic proximity Read ↗

Integrase strand transfer inhibitors in the management of HIV-positive individualsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.